© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Hepion Pharmaceuticals, Inc. (HEPA) stock declined over -7.76%, trading at $0.69 on NASDAQ, down from the previous close of $0.75. The stock opened at $0.74, fluctuating between $0.65 and $0.76 in the recent session.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Employees | 22 |
Beta | 1.845 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) stock price is $0.69 in the last trading session. During the trading session, HEPA stock reached the peak price of $0.76 while $0.65 was the lowest point it dropped to. The percentage change in HEPA stock occurred in the recent session was -7.76% while the dollar amount for the price change in HEPA stock was -$0.06.
The NASDAQ listed HEPA is part of Biotechnology industry that operates in the broader Healthcare sector. Hepion Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Daniel J. Trepanier Ph.D.
Senior Vice President of Drug Devel.
Dr. John Z. Sullivan-Bolyai
Part-Time Consultant
Mr. John T. Cavan
Chief Financial Officer
Dr. Stephen A. Harrison FACP, M.D.
Scientific Advisory Board Chair & Consultant Medical Director
Dr. Daren Ure Ph.D.
Chief Scientific Officer
Sharen Pyatetskaya
Director of Investor Relations
Dr. Launa J. Aspeslet Ph.D.
Chief Operating Officer
Dr. Todd M. Hobbs M.D.
Chief Medical Officer
Dr. Patrick R. Mayo Ph.D.
Senior Vice President of Clinical Pharmacology
Dr. Stephen A. Harrison M.D.
Scientific Advisory Board Chair & Consultant Medical Director
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.
Pres, Chief Executive Officer, Chief Scientific Officer & Director
HEPA's closing price is 25.1% higher than its 52-week low of $0.55 where as its distance from 52-week high of $5.30 is -86.95%.
Number of HEPA employees currently stands at 22.
Official Website of HEPA is: https://www.hepionpharma.com
HEPA could be contacted at phone 732 902 4000 and can also be accessed through its website. HEPA operates from 399 Thornall Street, Edison, NJ 08837, United States.
HEPA stock volume for the day was 94K shares. The average number of HEPA shares traded daily for last 3 months was 54.96K.
The market value of HEPA currently stands at $4.01M with its latest stock price at $0.69 and 5.8M of its shares outstanding.